KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Assets (2016 - 2025)

Historic Assets for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to $1.8 billion.

  • Medpace Holdings' Assets fell 1588.48% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 1588.48%. This contributed to the annual value of $2.1 billion for FY2024, which is 2680.05% up from last year.
  • Medpace Holdings' Assets amounted to $1.8 billion in Q3 2025, which was down 1588.48% from $1.6 billion recorded in Q2 2025.
  • Over the past 5 years, Medpace Holdings' Assets peaked at $2.1 billion during Q4 2024, and registered a low of $1.3 billion during Q2 2022.
  • Its 5-year average for Assets is $1.6 billion, with a median of $1.6 billion in 2025.
  • As far as peak fluctuations go, Medpace Holdings' Assets plummeted by 1852.12% in 2022, and later soared by 4017.84% in 2024.
  • Medpace Holdings' Assets (Quarter) stood at $1.7 billion in 2021, then fell by 18.52% to $1.4 billion in 2022, then increased by 22.5% to $1.7 billion in 2023, then increased by 26.8% to $2.1 billion in 2024, then decreased by 16.56% to $1.8 billion in 2025.
  • Its last three reported values are $1.8 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.9 billion during Q1 2025.